These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12950040)

  • 41. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
    Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection.
    Ison MG; Mishin VP; Braciale TJ; Hayden FG; Gubareva LV
    J Infect Dis; 2006 Mar; 193(6):765-72. PubMed ID: 16479509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
    Herlocher ML; Truscon R; Elias S; Yen HL; Roberts NA; Ohmit SE; Monto AS
    J Infect Dis; 2004 Nov; 190(9):1627-30. PubMed ID: 15478068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets.
    Ryan DM; Ticehurst J; Dempsey MH
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2583-4. PubMed ID: 8585752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relenza.
    McCauley J
    Curr Biol; 1999 Nov; 9(21):R796. PubMed ID: 10556097
    [No Abstract]   [Full Text] [Related]  

  • 46. [Influenza or flu-like infection? Diagnosis has consequences for therapy].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688203
    [No Abstract]   [Full Text] [Related]  

  • 47. Semi-quantitative detection of viral RNA in influenza A virus-infected mice for evaluation of antiviral compounds.
    Sauerbrei A; Ulbricht A; Wutzler P
    Antiviral Res; 2003 Mar; 58(1):81-7. PubMed ID: 12719010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.
    Drusano GL; Preston SL; Smee D; Bush K; Bailey K; Sidwell RW
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2115-8. PubMed ID: 11408232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid.
    Prince GA; Porter DD
    J Infect Dis; 1996 Mar; 173(3):598-608. PubMed ID: 8627023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma.
    Nozoe M; Iino T; Nagafuji K; Miyamoto T; Ito H; Gondo H; Harada M
    Intern Med; 2003 Nov; 42(11):1127-30. PubMed ID: 14686755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of interferon and cutisone on ultrastructure of pulmonary capillaries in experimental influenza.
    Chernukh AM; Krantchev AK
    Bibl Anat; 1967; 9():390-5. PubMed ID: 6043617
    [No Abstract]   [Full Text] [Related]  

  • 52. In vivo antiviral chemotherapy. I. Experimental design and statistical evaluation.
    Redman CE; Streightoff F; Jones M; Boniece WS; DeLong DC
    Antimicrob Agents Chemother (Bethesda); 1966; 6():497-502. PubMed ID: 5985278
    [No Abstract]   [Full Text] [Related]  

  • 53. In vivo antiviral chemotherapy. 3. Anti-influenza action of 1, 1-diaryl-2-propynyl carbamates.
    DeLong DC; Dillard RD; Easton NR; Streightoff F; Boniece WS; Redman CE
    Antimicrob Agents Chemother (Bethesda); 1966; 6():509-14. PubMed ID: 5985280
    [No Abstract]   [Full Text] [Related]  

  • 54. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment.
    Quispe-Laime AM; Bracco JD; Barberio PA; Campagne CG; Rolfo VE; Umberger R; Meduri GU
    Intensive Care Med; 2010 Jan; 36(1):33-41. PubMed ID: 19924393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy.
    Batool S; Chokkakula S; Song MS
    Microorganisms; 2023 Jan; 11(1):. PubMed ID: 36677475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors Limiting the Translatability of Rodent Model-Based Intranasal Vaccine Research to Humans.
    Cai L; Xu H; Cui Z
    AAPS PharmSciTech; 2022 Jul; 23(6):191. PubMed ID: 35819736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glucocorticoid therapy in respiratory illness: bench to bedside.
    Amratia DA; Viola H; Ioachimescu OC
    J Investig Med; 2022 Dec; 70(8):1662-1680. PubMed ID: 35764344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influenza antivirals and animal models.
    Caceres CJ; Seibert B; Cargnin Faccin F; Cardenas-Garcia S; Rajao DS; Perez DR
    FEBS Open Bio; 2022 Jun; 12(6):1142-1165. PubMed ID: 35451200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential benefits of precise corticosteroid therapy for critical COVID-19.
    Chen Q; Yang Q; Fang Y; Chen G; Lv X
    Respir Physiol Neurobiol; 2022 Mar; 297():103813. PubMed ID: 34801741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of aging on immunogenicity and efficacy of inactivated influenza vaccines in cotton rats
    Boukhvalova MS; Mortensen E; Mbaye A; McKay J; Blanco JCG
    Hum Vaccin Immunother; 2021 Jan; 17(1):133-145. PubMed ID: 32614696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.